Clinical Trials
Transforming Mental Health Care
At Cybin, our mission is to revolutionize mental healthcare by developing safe and effective treatments for mental health conditions, including depression and anxiety. We are conducting clinical trials to evaluate innovative therapies designed to address the unmet needs of individuals seeking better treatment options.
Participants in a Cybin clinical trial have the opportunity to contribute to groundbreaking research that could change the future of mental health care. We are currently investigating CYB003, a deuterated psilocin, which has shown promise in improving symptoms of depression quickly and sustainably in early studies. Additionally, we are advancing the development of CYB004, a deuterated DMT molecule being studied for its potential to address anxiety disorders.
These medicines are not currently approved to be sold in any country. The purpose of these trials is to show that they are safe and effective. Participation not only helps us advance science but also brings us one step closer to providing new hope for those struggling with mental health challenges. Each trial is conducted under rigorous safety standards and in close collaboration with healthcare professionals to ensure participants’ well-being throughout the process.
Ongoing Clinical Trials
Cybin currently has the following trials. You can click on the trial title for more information (if available) and on the recruitment link to find details on how to participate should you be interested.
Cybin currently has the
following trials. You can click on the
trial title for more information
(if available) and on the recruitment link to find details on how to participate should you be interested.
Trial Name: Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Link
Investigational Product: CYB003
Status: Participants invited following completion of APPROACH & EMBRACE
Condition: Major Depressive Disorder
Phase: 3
Location(s): Same as APPROACH & EMBRACE
Recruitment Link: Participants will need to complete either the APPROACH or EMBRACE trial to participate
Trial Name: A Study of a N, N-dimethyltryptamine
(DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD) Link
Investigational Product: CYB004
Status: Recruiting
Condition: Generalize Anxiety Disorder
Phase: 2
Location(s): USA (Atlanta, Miami, Murray) Link
Recruitment Link: Apply For Trial Here
Trial Name
Investigational
Product
Status
Condition
Phase
Location(s)
Recruitment Link
A Study of a Psilocybin
Analog (CYB003) in Humans With Major Depressive Disorder (APPROACH)
Link
CYB003
Recruiting
Major
Depressive
Disorder
3
Czech Republic,
Germany, Poland,
Spain, USA
Link
TBC
A Phase 3 Trial to
Assess CYB003 in Major Depressive Disorder (EMBRACE)
Link
CYB003
Not Recruiting
Major
Depressive
Disorder
3
Australia, Greece,
Ireland, Netherlands,
Poland, UK, USA
Link
TBC
Phase III Long-term Extension Trial to
Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Link
CYB003
Participants invited following
completion of APPROACH &
EMBRACE
Major
Depressive
Disorder
3
Same as
APPROACH &
EMBRACE
Participants will need to
complete either the APPROACH
or EMBRACE trial to participate
A Study of a N, N-dimethyltryptamine
(DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)
Link
CYB004
Recruiting
Generalized
Anxiety
Disorder
2
USA
(Atlanta, Miami, Murray)
Link
